Paradigm Biopharmaceuticals (ASX:PAR) Total Operating Expense: A$38.98 Mil (TTM As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
26 GF Score
Price A$0.18
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Total Operating Expense?

Paradigm Biopharmaceuticals ASX:PAR +9.09% 26 Total Operating Expense is A$38.98 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals's Total Operating Expense for the six months ended in Dec. 2025 was A$21.92 Mil. Paradigm Biopharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$38.98 Mil.

Paradigm Biopharmaceuticals Total Operating Expense Related Terms

Paradigm Biopharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Total Operating Expense Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.31 47.93 60.07 65.25 23.47

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.30 14.95 6.42 17.06 21.92
ASX:PAR
26GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$38.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of A$38.98 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Total Operating Expense of A$38.98 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Total Operating Expense too high?
Paradigm Biopharmaceuticals' current Total Operating Expense is A$38.98 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Total Operating Expense compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Total Operating Expense of A$38.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Total Operating Expense is A$38.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Total Operating Expense of A$38.98 Mil. The current Total Operating Expense is A$38.98 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Total Operating Expense is A$38.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
26GF Score

Get the complete analysis for ASX:PAR

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price